YOLFTbeta
Tango Therapeutics Inc

Tango Therapeutics Inc

TNGX · NASDAQ · Healthcare / Biotechnology

25.50USD+0.65 (+2.62%)

Price History

Full chart

Market Stats

Previous Close24.85
Open24.76
Day Range23.66 – 25.58
52-Week Range7.49 – 34.39
Volume2.68M
Market Cap4.12B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.38
Dividend Yield0.00%
Beta1.22
50-Day Avg23.32
200-Day Avg22.63

About

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Malte Peters M.D.
  • Employees137
  • Headquarters201 Brookline Avenue, Boston, MA, United States, 02215, USA
  • Websitehttps://www.tangotx.com

Leadership

  • Dr. Malte Peters M.D.President, CEO & Director · b. 1962
  • Dr. Barbara L. Weber M.D.Executive Officer · b. 1957
  • Dr. Adam S. Crystal M.D., Ph.D.President of Research & Development · b. 1977
  • Prof. Alan Ashworth FRS, Ph.D.Founder & Member of Scientific Advisory Board · b. 1961
  • Dr. William G. Kaelin Jr., M.D.Founder & Member of Scientific Advisory Board · b. 1958
  • Dr. Antoni Ribas M.D., Ph.D.Founder & Member of Scientific Advisory Board · b. 1967
  • Mr. Matthew Gall M.B.A.Chief Financial Officer · b. 1977
  • Ms. Elizabeth Pingpank HickinVP of IR & Corporate Communications
  • Ms. Julie FogartySenior VP, General Counsel & Corporate Secretary
  • Ms. Julie CarreteroChief Human Resources Officer · b. 1972

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue24.65M7.66M37.04M24.86M36.53M42.07M62.38M
Growth (%)--68.94%+383.83%-32.89%+46.93%+15.17%+48.29%
Cost of Revenue32.27M1.63M1.97M4.03M115.20M2.50M2.28M
Gross Profit-7.63M6.03M37.04M24.86M36.53M42.07M60.10M
Gross Margin-30.93%78.77%100.00%100.00%100.00%100.00%96.34%
Operating Expense7.54M58.23M95.23M135.93M150.70M187.66M171.39M
Operating Income-15.16M-52.20M-58.19M-111.07M-114.17M-145.59M-111.29M
Operating Margin-61.51%-681.82%-157.09%-446.79%-312.57%-346.09%-178.39%
EBITDA-14.52M-51.25M-57.29M-109.46M-99.19M-127.59M-99.31M
EBITDA Margin-58.90%-669.46%-154.67%-440.32%-271.57%-303.30%-159.19%
Net Income-14.10M-51.97M-58.23M-108.18M-101.74M-130.30M-101.59M
Net Income Margin-57.18%-678.84%-157.21%-435.14%-278.54%-309.73%-162.85%
R&D32.27M49.99M77.64M105.91M115.20M143.92M132.16M
R&D as % of Total Revenue130.93%652.96%209.59%426.01%315.38%342.10%211.86%
Interest Expense001.14M2.95M---
Interest Expense % of Total Revenue0.00%0.00%3.09%11.86%---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets55.76M207.25M500.15M436.47M402.57M316.49M398.69M
Total Liabilities47.86M168.65M155.41M186.99M149.46M116.97M52.51M
Total Equity7.91M38.60M344.75M249.48M253.11M199.52M346.18M
Cash22.89M28.38M142.75M59.97M66.39M69.53M112.28M
Total Debt8.54M7.88M1.50M41.13M38.92M36.49M33.57M
Net Debt-14.35M-20.50M-141.24M-18.84M-27.46M-33.04M-78.71M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-24.80M70.07M-59.53M-109.08M-117.98M-131.50M-138.89M
Investing Cash Flow848.00K-145.47M-183.43M26.40M41.43M86.13M-40.87M
Financing Cash Flow11.00M80.88M357.32M1.61M82.41M47.66M222.50M
Capital Expenditure1.82M1.11M1.84M7.69M1.53M754.00K1.05M
Free Cash Flow-26.62M68.97M-61.36M-116.77M-119.51M-132.25M-139.93M
FCF to OCF107.33%98.42%103.09%107.05%101.29%100.57%100.75%

Earnings

Report DateJul 30, 2020Nov 13, 2020Mar 31, 2021May 14, 2021Aug 6, 2021Nov 9, 2021Mar 28, 2022May 11, 2022Aug 10, 2022Nov 10, 2022Mar 27, 2023May 9, 2023Aug 7, 2023Nov 8, 2023Mar 18, 2024May 8, 2024Aug 7, 2024Nov 6, 2024Mar 17, 2025May 12, 2025Aug 5, 2025Nov 4, 2025Mar 5, 2026May 13, 2026Aug 11, 2026Nov 3, 2026Nov 9, 2026Mar 4, 2027
EPS Estimate0.00----0.14-0.28-0.27-0.27-0.32-0.32-0.35-0.35-0.34-0.34-0.28-0.31-0.35-0.37-0.34-0.35-0.34-0.07-0.33-0.30-0.31-0.34-0.34-0.39
EPS Actual0.00-0.00-0.00-0.01-0.16-0.28-0.25-0.29-0.28-0.33-0.33-0.32-0.23-0.23-0.32-0.35-0.24-0.27-0.34-0.36-0.350.13-0.29-0.32-0.37--0.39-
Surprise-----10.34%0.00%7.41%-7.41%12.50%-3.13%5.71%8.57%32.35%32.35%-14.29%-12.90%31.43%27.03%0.82%-2.86%-2.94%285.71%12.12%-7.85%-19.35%--14.71%-
Timing----After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap4.12B
Enterprise Value2.91B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.93
EPS-1.38
Book Value5.79
Revenue (TTM)0
Gross Profit (TTM)-151.76M
EBITDA-226.75M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-36.48%
Return on Assets-22.97%
Shares Outstanding169.46M
Shares Float121.28M
Beta1.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 13 analystsTarget 47.00
  • Strong Buy
    11
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
128.21%
Insiders
1.18%
Retail / Other
0.00%

Top Institutional Holders

  • RTW INVESTMENTS, LLC
    13.90M8.24%
  • BlackRock Inc
    12.44M7.38%
  • FMR Inc
    12.33M7.31%
  • Farallon Capital Management, L.L.C.
    12.28M7.28%
  • Boxer Capital Management, LLC
    10.88M6.45%
  • The Goldman Sachs Group Inc
    9.98M5.92%
  • TCG Crossover Management, LLC
    9.08M5.39%
  • TRV GP IV, LLC
    6.37M3.78%
  • Paradigm Biocapital Advisors LP
    6.36M3.77%
  • T. Rowe Price Associates, Inc.
    6.35M3.77%
  • Siren, L.L.C.
    6.18M3.66%
  • State Street Corp
    5.98M3.55%
  • Vanguard Capital Management, LLC
    5.96M3.53%
  • Adage Capital Partners Gp LLC
    5.60M3.32%
  • Jupiter Topco LLC
    5.06M3.00%
  • Deep Track Capital, LP
    4.20M2.49%
  • Deerfield Management Co
    4.19M2.49%
  • Woodline Partners LP
    4.00M2.37%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    4.62M2.74%
  • State Street® SPDR® S&P® Biotech ETF
    4.36M2.59%